Recent research has indicated that selective serotonin reuptake inhibitors (SSRIs) may be an effective option for the treatment of vasomotor symptoms associated with menopause. However, it has been documented in some recent observational studies that [...]
Last year, the FDA approved the first non-hormonal treatment for hot flashes – a 7.5-mg formulation of the selective serotonin reuptake inhibitor (SSRI) paroxetine which was marketed under the name of Brisdelle. A new study [...]
The FDA recently approved a 7.5-mg formulation of the selective serotonin reuptake inhibitor (SSRI) paroxetine mesylate for the treatment of hot flashes.  It will be marketed under the name of Brisdelle.
